DemeRx
Fort Lauderdale, US · Founded 2010 · Florida corporation
DemeRx is a clinical-stage biopharmaceutical company developing DMX-1001 (oral noribogaine), an investigational therapy for alcohol use disorder and other substance use disorders. Its approach targets neuroplasticity and dysregulated stress and reward pathways in the brain.
Founders & leadership
HW
Holger WeisExecutive
JL
Jeffrey L. RaneyExecutive
SG
Steve GorlinNamed on SEC filing
Board
HM
Henry MellonBoard director
CK
Charles KoobBoard director
BH
Bruce HackBoard director
PN
Peter NejesBoard director
SC
Skip ClemmonsBoard director
Reported raises · per SEC filings
Form D private placements$289.6K disclosed across 1 round · 2015
▶$289.6KraisedMay 2015 · 9 investors · PharmaceuticalsRule 506(b)
▶$289.6KraisedMay 2015 · 9 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Henry MellonDirector
- Holger WeisExecutive Officer
- Jeffrey L. RaneyExecutive Officer
- Charles KoobDirector
- Bruce HackDirector
- Peter NejesDirector
- Steve GorlinDirector
- Skip ClemmonsDirector
- Offering amount
- $500K
- Amount sold
- $289.6K
- Minimum investment
- $1K
- First sale
- Apr 2015
- Incorporated
- Corporation, Florida, 2010
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Frequently asked questions
- What does DemeRx do?
- DemeRx is a clinical-stage biopharmaceutical company developing DMX-1001 (oral noribogaine), an investigational therapy for alcohol use disorder and other substance use disorders. Its approach targets neuroplasticity and dysregulated stress and reward pathways in the brain.
- How much funding has DemeRx raised?
- DemeRx has disclosed $289.6K raised across 1 round.
- Where is DemeRx headquartered?
- DemeRx is headquartered in Fort Lauderdale, US.